Advertisement
Collaboration › Details
Servier–Saga Diagnostics: pharmacogenomic services, 202001–202201 collab extension 2y services usingSAGAsafe technology in cancer studies
Period | 2020-01-28 � 2021-12-31 | |
Partner, 1st | Laboratoires Servier, Les | |
Group | Servier (Group) | |
Partner, 2nd | Saga Diagnostics AB | |
Product | pharmacogenomic/pharmacogenetic services | |
Product 2 | SAGAsafe® technology | |
Saga Diagnostics AB. (1/28/20). "Press Release: Saga Diagnostics Extends Its Collaboration with Servier to Use Ultrasensitive SAGAsafe Technology in Cancer Clinical Trials". Lund.
SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, today announces it has entered service agreements with the international pharmaceutical company Servier, based in Paris, France.
“These deals exemplify the increased demand we are experiencing for our offerings of ultrasensitive cancer analysis services and analysis kits. We are excited to be working with Servier, who continues to choose us for important translational oncology projects.”
– Lao Saal, CEO of SAGA Diagnostics.
The collaboration will be covering a total of three preclinical/clinical studies and is scheduled to run for approximately two years. In the course of these projects, SAGA Diagnostics will be developing assays and performing liquid biopsy tests on patients from multiple Servier clinical studies using the SAGAsafe® technology (formerly known as IBSAFE®) to identify and quantify circulating tumor DNA (ctDNA).
SAGAsafe® technology is a patented improvement of digital PCR that enables approximately 100-fold increased sensitivity compared to competitor methods, and can be used to quantify mutations in tissue samples as well as liquid biopsies such as blood plasma with unprecedented performance to a limit of detection of ~0.001% mutant allele frequency. The analyses will be run in the SAGA Diagnostics central laboratory in Lund, Sweden.
“We have been impressed by the service and ultra-sensitivity performance of SAGAsafe’s analyses and are looking forward to continue working together. Involving the SAGAsafe technology in these studies means that Servier will now be able to monitor effects at an earlier stage ensuring that we do not miss out on any insights.”
– Brian Lockhart, Director of CentEx-Biotechnology, Servier.
SAGAsafe® is part of a portfolio of ultrasensitive technologies, which also includes SAGAsign® (formerly known as KROMA™) for monitoring chromosomal rearrangements, as well as novel technologies in development. SAGA offers both off-the-shelf analysis services and kits as well as custom-tailored solutions to fit customers’ needs. SAGA’s molecular tools are being used in clinical trials and hospitals for detecting actionable mutations, monitoring treatment response, measuring minimal residual disease, and identifying resistance mechanisms to help direct therapy.
Contact:
Åke Nilsson, BD Director
bd@sagadiagnostics.com
Phone: +46 (0)733 01 72 42
About SAGA Diagnostics AB
SAGA Diagnostics is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and provides the basis for optimal decision-making.
Follow us on Twitter @SAGAdiagnostics and LinkedIn.
Record changed: 2020-02-03 |
Advertisement
More documents for Servier (Group)
- [1] Owkin. (10/17/23). "Press Release: Servier Partners with Owkin with the Aim of Discovering and Developing AI-driven Precision Therapeutics"....
- [2] Aqemia SAS. (1/9/23). "Press Release: Servier and Aqemia Extend Collaboration on Undruggable Target in Immuno-Oncology". Paris....
- [3] Aqemia SAS. (12/16/21). "Press Release: Aqemia and Servier Announce AI and Quantum Physics-drive Drug Discovery Collaboration in Immuno-oncology". Paris....
- [4] Servier. (6/16/21). "Press Release: Servier and PRISM BioLab Enter Drug Discovery Collaboration for a Novel Target". Paris & Tokyo....
- [5] MiNA Therapeutics Ltd.. (1/21/21). "Press Release: Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases". Paris & London....
- [6] Cytokinetics, Inc.. (12/23/20). "Press Release: Cytokinetics Regains European Rights to Omecamtiv Mecarbil". South San Francisco, CA....
- [7] Servier. (12/21/20). "Press Release: Servier to Acquire Agios Pharmaceuticals’ Oncology Business". Paris & Boston, MA....
- [8] Cytokinetics, Inc.. (11/23/20). "Press Release: Cytokinetics Regains Rights to Develop and Commercialize Omecamtiv Mecarbil and AMG 594 from Amgen". South San Francisco, CA....
- [9] Galapagos N.V.. (10/15/20). "Press Release: Galapagos and Servier Report Topline Results for ROCCELLA Phase 2 Clinical Trial with GLPG1972/S201086 in Knee Osteoarthritis Patients". Mechelen & Paris....
- [10] Servier. (10/6/20). "Press Release: The Servier Group Accelerates Its Digital Transformation and Has Named Virginie Dominguez as Chief Digital Officer". Paris....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top